Lupin Ltd

BSE: LUPIN500257ISIN INE326A01037

Healthcare
Pharmaceuticals
BSE 100

BSE listing

Share price

₹2,144.70+52.70 (+2.52%)

as of 18 Sep 2026

52W high: ₹2,530.00
52W low: ₹1,900.30
Off 52W high: -15.23%
1M return: -3.39%
3M return: -8.81%
6M return: -7.65%
1Y return: +4.82%
20D avg volume: 67,955
50 DMA: ₹2,277.88
200 DMA: ₹2,255.94

Key ratios Consolidated

Market cap: ₹98,070 Cr
Current price: ₹2,144.70
52W high / low: ₹2,530.00 / ₹1,900.30
Face value: ₹2.00
P/E: 17.67
P/B: —
EPS (TTM): ₹121.40
Book value / share: —
ROE: —
ROCE: 28.40%
Operating margin: —
Net margin: —
Debt / equity: 0.26
Net debt: ₹1,742 Cr
Interest cover: 16.82
Dividend yield: 0.84%
Dividend / share (TTM): ₹18.00
Payout: 14.83%
Cash conversion cycle: 111.1 days

About

In plain English

Lupin Ltd is a global pharmaceutical company that makes and sells both generic and branded medicines, as well as the raw ingredients (APIs) that go into them. Their biggest product categories include generic versions of popular drugs like Farxiga (for diabetes and heart failure), complex drugs like inhalers for asthma and injectables for hospital use, and biosimilars (near-copies of biologic drugs) such as Ranibizumab for eye disease. They also sell over-the-counter health products under the LupinLife brand and run diagnostic labs. Their customers include patients, doctors, hospitals, pharmacies, and governments across over 100 countries. The company makes money by manufacturing these medicines at scale and supplying them to wholesalers, retailers, and healthcare providers, with the United States and India being their largest markets.

AI-generated summary, written from the company's own filings and disclosures. Every figure elsewhere on this page comes from exchange data, not from a model. See our editorial standards. Generated 1 Jul 2026.

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	8,277	7,475	7,168	7,048	6,268	5,667	5,768	5,673	5,600	4,961	5,197	5,039
	130.32	140.71	114.70	90.00	79.04	56.95	53.71	42.29	67.78	29.25	29.37	40.40
	6,390	5,556	5,334	5,131	4,932	4,828	4,750	4,660	4,675	4,492	4,491	4,449
	1,312	1,231	1,125	1,139	1,127	1,109	1,084	1,118	1,146	1,094	1,107	990.99
	842.27	708.41	719.73	724.92	713.95	575.69	766.39	659.98	640.56	661.11	676.12	854.74
	1,383	1,243	1,143	1,106	1,083	1,001	984.39	1,008	971.04	900.22	889.24	860.71
	109.64	120.16	114.98	107.59	91.76	89.10	66.89	70.87	68.01	71.29	74.01	80.64
	452.85	446.79	312.96	316.77	298.98	393.18	271.45	256.92	247.71	457.10	257.20	247.85
	2,355	1,895	1,884	1,776	1,686	1,659	1,696	1,667	1,598	1,490	1,560	1,552
	2,017	2,059	1,949	2,007	1,416	895.84	1,071	1,055	993.03	497.71	736.10	629.67
	0.00	-131.34	-426.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	2,017	1,928	1,522	2,007	1,416	895.84	1,071	1,055	993.03	497.71	736.10	629.67
	600.38	459.33	341.53	522.14	194.08	113.46	212.41	195.38	187.49	129.49	117.40	134.35
	1,417	1,469	1,181	1,485	1,221	782.38	858.86	859.48	805.54	368.22	618.70	495.32
	30.95	31.96	25.74	32.36	26.70	16.93	18.75	18.70	17.58	7.89	13.47	10.76
Key metrics
	2,580	2,495	1,950	2,431	1,806	1,378	1,410	1,383	1,309	1,026	1,067	958.16
	31.20%	33.40%	27.20%	34.50%	28.80%	24.30%	24.40%	24.40%	23.40%	20.70%	20.50%	19.00%
	17.10%	19.60%	16.50%	21.10%	19.50%	13.80%	14.90%	15.20%	14.40%	7.40%	11.90%	9.80%
	—	8.00%	—	9.30%	—	4.90%	—	—	—	—	—	—
	32.00%	31.90%	24.30%	24.20%	11.90%	14.20%	11.00%	12.60%	—	—	—	—
	16.00%	87.70%	37.50%	72.80%	51.60%	112.50%	38.80%	73.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	29,967	27,958	22,708	20,011	16,642	16,405	15,163	15,375	16,718	15,804
	475.73	424.45	195.82	120.17	73.36	141.69	136.29	483.76	364.02	150.35
	22,410	20,952	18,889	17,709	15,999	17,920	13,624	14,353	15,229	13,947
	4,807	4,622	4,457	4,142	3,688	3,236	3,170	3,164	3,560	2,955
	2,995	2,867	2,643	2,959	2,938	3,444	2,677	2,258	2,460	2,156
	4,875	4,575	3,964	3,495	3,087	2,989	2,826	2,987	3,151	2,865
	452.37	434.49	294.87	311.61	274.30	142.77	140.64	362.98	307.83	204.35
	1,529	1,376	1,169	1,197	880.69	1,659	887.41	970.22	1,085	—
	7,910	7,241	6,618	6,073	5,054	4,838	4,408	4,603	4,839	4,518
	8,032	7,430	4,015	2,422	716.49	-1,373	1,675	1,505	1,853	2,008
	-557.91	-557.91	0.00	0.00	0.00	0.00	0.00	-752.07	-339.98	-1,464
	7,474	6,873	4,015	2,422	716.49	-1,373	1,675	753.29	1,513	543.29
	1,923	1,517	708.74	486.70	268.80	137.15	448.52	1,157	901.69	288.46
	5,551	5,355	3,306	1,936	447.69	-1,509	1,228	-269.78	615.48	258.35
	121.01	116.75	71.95	42.05	9.46	-33.65	27.09	-8.83	—	—
Key metrics
	9,456	8,683	5,479	3,931	1,871	428.91	2,703	2,086	2,906	747.64
	31.56%	31.10%	24.10%	19.60%	11.20%	2.60%	17.80%	13.60%	17.40%	4.70%
	18.52%	19.20%	14.60%	9.70%	2.70%	-9.20%	8.10%	-1.80%	3.70%	1.60%
	—	28.40%	21.30%	—	—	—	—	—	—	—
	—	23.10%	13.50%	20.20%	1.40%	8.20%	-1.40%	-8.00%	5.80%	—
	—	62.00%	70.80%	332.30%	129.70%	-222.90%	555.20%	-143.80%	138.20%	—
	—	5,491	-1,252	—	—	—	—	—	—	—
	—	1.41	0.13	—	—	—	—	—	—	—
	—	0.26	0.29	—	—	—	—	—	—	—
	—	1,742	3,533	—	—	—	—	—	—	—
	—	111.1	128.9	—	—	—	—	—	—	—
Balance sheet
	—	38,365	29,205	—	—	—	—	—	—	—
	—	24,027	16,799	—	—	—	—	—	—	—
	—	4,168	1,544	—	—	—	—	—	—	—
	—	6,604	5,497	—	—	—	—	—	—	—
	—	6,083	5,476	—	—	—	—	—	—	—
	—	1,543	1,252	—	—	—	—	—	—	—
	—	5,449	5,148	—	—	—	—	—	—	—
	—	4,173	2,958	—	—	—	—	—	—	—
	—	12,651	8,961	—	—	—	—	—	—	—
	—	5,910	5,077	—	—	—	—	—	—	—
	—	4,267	3,310	—	—	—	—	—	—	—
	—	1,643	1,766	—	—	—	—	—	—	—
	—	22,513	17,294	—	—	—	—	—	—	—
Cash flow
	—	7,546	429.94	—	—	—	—	—	—	—
	—	-4,076	-1,602	—	—	—	—	—	—	—
	—	-845.87	1,732	—	—	—	—	—	—	—
	—	2,055	1,682	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	7,172	5,235	4,501	4,068	5,709	4,486	4,208	4,106	4,168	3,396	4,116	3,659
	102.48	88.83	99.80	70.00	54.14	48.79	55.30	32.62	38.22	31.34	23.16	25.60
	3,664	3,169	3,099	3,095	3,175	2,981	2,969	3,155	3,123	2,999	3,055	2,989
	1,051	995.53	909.55	864.14	909.14	923.60	912.78	907.04	973.30	884.81	836.97	855.88
	308.90	274.58	296.13	309.68	311.93	277.74	331.27	312.43	325.41	344.56	364.47	469.29
	719.69	660.65	631.51	608.83	643.89	552.42	576.37	594.51	588.77	517.07	522.47	532.18
	35.56	38.77	36.02	27.78	18.90	33.85	19.55	17.55	13.55	13.49	11.36	15.32
	190.01	177.05	178.68	174.72	176.73	207.98	152.52	145.77	141.42	290.04	145.18	149.48
	1,370	1,056	1,065	1,015	1,154	1,011	1,120	1,089	1,116	966.65	1,037	1,080
	3,610	2,155	1,502	1,043	2,588	1,553	1,294	984.05	1,083	428.16	1,084	696.04
	0.00	447.73	-633.84	592.68	0.00	0.00	-77.22	—	—	—	—	—
	3,610	2,602	867.94	1,636	2,588	1,553	1,217	984.05	1,083	428.16	1,084	696.04
	895.46	438.66	150.49	278.46	460.08	261.74	232.39	176.29	193.74	44.08	167.52	147.43
	2,715	2,164	717.45	1,357	2,128	1,291	984.67	807.76	889.18	384.08	916.44	548.61
	59.37	47.35	15.71	29.72	46.60	28.30	21.58	17.71	19.51	8.43	20.14	12.06
Key metrics
	3,836	2,818	1,083	1,838	2,784	1,795	1,389	1,147	1,238	731.69	1,240	860.84
	53.50%	53.80%	24.10%	45.20%	48.80%	40.00%	33.00%	27.90%	29.70%	21.50%	30.10%	23.50%
	37.90%	41.30%	15.90%	33.40%	37.30%	28.80%	23.40%	19.70%	21.30%	11.30%	22.30%	15.00%
	—	8.40%	—	5.90%	—	6.30%	—	—	—	—	—	—
	25.60%	16.70%	7.00%	-0.90%	37.00%	32.10%	2.20%	12.20%	—	—	—	—
	27.60%	67.60%	-27.10%	68.00%	139.30%	236.20%	7.40%	47.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	20,976	19,513	16,968	14,666	11,259	11,772	11,056	11,026	11,356	10,088
	361.11	312.77	174.05	106.73	91.26	150.42	129.09	475.19	291.34	131.12
	13,027	12,538	12,227	11,989	10,823	12,084	9,555	9,689	8,965	8,425
	3,820	3,678	3,717	3,407	3,151	2,817	2,741	2,753	2,693	2,260
	1,189	1,192	1,247	1,634	1,526	1,893	1,523	1,483	1,347	1,130
	2,621	2,545	2,312	2,096	1,934	1,918	1,696	1,703	1,515	1,442
	138.13	121.47	84.50	56.35	98.44	73.47	40.62	52.59	35.47	33.24
	720.46	707.18	647.69	724.75	548.34	514.19	502.83	518.75	426.30	389.81
	4,505	4,289	4,258	4,095	3,563	3,299	3,134	3,208	3,095	3,086
	8,310	7,288	4,914	2,785	527.14	-161.53	1,630	1,811	2,682	1,794
	406.57	406.57	-77.22	—	—	—	—	-759.21	-339.98	—
	8,716	7,694	4,837	2,785	527.14	-161.53	1,630	1,052	2,342	1,794
	1,763	1,328	864.16	458.60	101.93	27.17	371.08	324.70	803.54	449.27
	6,953	6,367	3,973	2,326	425.21	-188.70	1,259	727.55	1,539	1,345
	152.15	139.38	87.10	51.10	9.35	-4.16	27.77	16.07	—	—
Key metrics
	9,575	8,523	5,569	3,566	1,174	426.13	2,173	1,624	2,804	2,217
	45.65%	43.70%	32.80%	24.30%	10.40%	3.60%	19.70%	14.70%	24.70%	22.00%
	33.15%	32.60%	23.40%	15.90%	3.80%	-1.60%	11.40%	6.60%	13.60%	13.30%
	—	25.00%	19.50%	—	—	—	—	—	—	—
	—	15.00%	15.70%	30.30%	-4.40%	6.50%	0.30%	-2.90%	12.60%	—
	—	60.20%	70.80%	447.00%	325.30%	-115.00%	73.00%	-52.70%	14.40%	—
	—	4,823	1,150	—	—	—	—	—	—	—
	—	0.87	0.62	—	—	—	—	—	—	—
	—	0.02	0.01	—	—	—	—	—	—	—
	—	465.25	-115.96	—	—	—	—	—	—	—
	—	144.9	148.8	—	—	—	—	—	—	—
Balance sheet
	—	36,103	28,432	—	—	—	—	—	—	—
	—	15,595	11,895	—	—	—	—	—	—	—
	—	111.63	341.80	—	—	—	—	—	—	—
	—	6,922	5,664	—	—	—	—	—	—	—
	—	3,351	3,227	—	—	—	—	—	—	—
	—	1,026	1,114	—	—	—	—	—	—	—
	—	3,169	3,446	—	—	—	—	—	—	—
	—	2,529	1,969	—	—	—	—	—	—	—
	—	4,832	3,233	—	—	—	—	—	—	—
	—	576.88	225.84	—	—	—	—	—	—	—
	—	576.88	0.00	—	—	—	—	—	—	—
	—	0.00	225.84	—	—	—	—	—	—	—
	—	30,134	24,278	—	—	—	—	—	—	—
Cash flow
	—	5,540	2,445	—	—	—	—	—	—	—
	—	-5,649	-1,766	—	—	—	—	—	—	—
	—	-121.13	-460.23	—	—	—	—	—	—	—
	—	717.04	1,294	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +20.12%
Sales CAGR 5Y: +12.03%
Sales CAGR 10Y: —
Profit CAGR 3Y: +146.47%
Profit CAGR 5Y: +38.29%
Profit CAGR 10Y: —
Sales YoY (TTM): +13.33%
Profit YoY (TTM): +33.41%

Consolidated

Sales CAGR 3Y: +18.88%
Sales CAGR 5Y: +13.02%
Sales CAGR 10Y: —
Profit CAGR 3Y: +128.70%
Profit CAGR 5Y: +34.25%
Profit CAGR 10Y: —
Sales YoY (TTM): +28.19%
Profit YoY (TTM): +49.13%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 46.85%

Holder	Type	Holding	Previous	Change
Lupin Investments Private Limited	Promoter	45.31%	—	—
Hdfc Trustee Company Ltd. A/C Hdfc Balanced Advantage Fund	Public	4.37%	—	—
Life Insurance Corporation Of India	Public	4.09%	—	—
Nps Trust- A/C Hdfc Pension Fund Management Limited Scheme E - Tier I	Public	2.75%	—	—
Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund	Public	2.60%	—	—
Sbi Elss Tax Saver Fund	Public	1.96%	—	—
Mirae Asset Large & Midcap Fund	Public	1.74%	—	—
Hdfc Life Insurance Company Limited	Public	1.10%	—	—
Manju D Gupta	Promoter	0.85%	—	—
Nilesh Gupta	Promoter	0.20%	—	—
Anuja Gupta	Promoter	0.16%	—	—
D B Gupta HUF (Nilesh Deshbandhu Gupta, Karta of HUF)	Promoter	0.14%	—	—
Vinita Gupta	Promoter	0.07%	—	—
Richa Gupta	Promoter	0.05%	—	—
Kavita Gupta	Promoter	0.04%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Intimation about participating in the Analyst/Institutional Investors Meet.8 Sep 2026 · Company Update / Analyst / Investor Meet
Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP.4 Sep 2026 · Company Update / Press Release / Media Release
ESG Rating by Crisil ESG Ratings & Analytics Ltd.28 Aug 2026 · Company Update / General
Intimation of allotment of 30967 equity shares under ESOP.25 Aug 2026 · Company Update / Allotment of ESOP / ESPS
ESG Rating by ESG Risk Assessment and Insights Limited.24 Aug 2026 · Company Update / General
VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.20 Aug 2026 · Company Update / General
Intimation of Demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.18 Aug 2026 · Company Update / Demise
Lupin Announces Approval from U.S. FDA for Pitolisant Tablets.17 Aug 2026 · Company Update / Press Release / Media Release
Transcript of Q1 FY2027 Earnings Conference Call12 Aug 2026 · Company Update / Earnings Call Transcript
Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States.10 Aug 2026 · Company Update / Press Release / Media Release
Intimation about participating in the Analyst/Institutional Investors Meet.10 Aug 2026 · Company Update / Analyst / Investor Meet
Copies of Newspaper publication in respect of Unaudited Financial Results of the Company for the quarter ended June 30, 2026.8 Aug 2026 · Company Update / Newspaper Publication
Link of Audio recording of the Earnings Call-Q1 FY27.7 Aug 2026 · Company Update / Analyst / Investor Meet
Investor Presentation (Revised) - Q1 FY27 Results7 Aug 2026 · Company Update / Investor Presentation
Investor Presentation- Q1 FY20276 Aug 2026 · Company Update / Investor Presentation
Lupin Q1 FY2027 Results6 Aug 2026 · Company Update / Press Release / Media Release
Board Meeting Outcome for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.6 Aug 2026 · Result / Financial Results
Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.6 Aug 2026 · Board Meeting / Outcome of Board Meeting
Details of Voting Results of the Forty-Fourth Annual General Meeting along with the Consolidated Scrutinizer''s Report.4 Aug 2026 · AGM/EGM / AGM
Proceedings of the Forty-Fourth Annual General Meeting held on August 04, 2026.4 Aug 2026 · AGM/EGM / AGM
Lupin Announces the approval of Diazepam Injection, USP in the United States.31 Jul 2026 · Company Update / Press Release / Media Release
Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection.31 Jul 2026 · Company Update / Press Release / Media Release
Schedule of Earnings Call for Q1 FY2722 Jul 2026 · Company Update / Analyst / Investor Meet
Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated ....22 Jul 2026 · Board Meeting / Board Meeting
Lupin Inc. U.S.A., wholly owned subsidiary of the Company has entered into a licensing agreement in exchange of 332,000 Common Shares of Kaveri Therapeutics, Inc. U.S.A.21 Jul 2026 · Company Update / Acquisition
Copy of Newspaper Advertisement relating to Annual General Meeting and e-voting related information.14 Jul 2026 · Company Update / Newspaper Publication
Lupin Recognized Among India''s Best Employers in the Nation-Builders Category by Great Place to Work India 2026.14 Jul 2026 · Company Update / Press Release / Media Release
Business Responsibility and Sustainability Report of the Company for FY 2025-26.13 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Integrated Report of the Company for FY 2025-26.13 Jul 2026 · Others / Reg. 34 (1) Annual Report
Notice of the Forty-Fourth Annual General Meeting of the Company and Integrated Report for FY 2025-26.13 Jul 2026 · AGM/EGM / AGM
Copy of Newspaper Advertisement relating to Annual General Meeting, Record Date and other related information.9 Jul 2026 · Company Update / Newspaper Publication
Intimation of Record Date for payment of final Dividend.8 Jul 2026 · Corp. Action / Record Date
Intimation of the Forty-Fourth Annual General Meeting to be held on Tuesday, August 04, 2026, at 04.00 p.m. (IST) through Video Conferencing/ Other Audio Visual Means.8 Jul 2026 · AGM/EGM / AGM
Intimation of allotment of 2358 equity shares under ESOP.8 Jul 2026 · Company Update / Allotment of ESOP / ESPS
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on June 30, 2026.8 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Lupin Named Among World''s Most Sustainable Companies by TIME and Statista.6 Jul 2026 · Company Update / Press Release / Media Release
Lupin Receives EIR from U.S. FDA for its Somerset Facility with VAI Classification.1 Jul 2026 · Company Update / Press Release / Media Release
Updates on acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. (''MPPI''), a subsidiary company and Buyback of shares by MPPI.1 Jul 2026 · Company Update / Acquisition
Lupin Announces EMA Approval for NaMuscla Expansion for Pediatric Indication with New Strengths.1 Jul 2026 · Company Update / Press Release / Media Release
Intimation regarding Grant of 65,251 Stock Options under Lupin Employees Stock Option Scheme 2025.30 Jun 2026 · Company Update / Allotment of ESOP / ESPS

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 18.0000	17 Jul 2026	17 Jul 2026	—
Final Dividend - Rs. - 12.0000	25 Jul 2025	25 Jul 2025	—
Final Dividend - Rs. - 8.0000	16 Jul 2024	16 Jul 2024	—

Board meetings

6 Aug 2026 Board Meeting - Financial Results